Investors News Coverage Nov 07, 2019Rafael Pharmaceuticals Joins the Pancreatic Cancer Action Network's Scientific & Medical Affairs Industry Membership Oct 30, 2019Rafael Pharmaceuticals Appoints Chief Medical Officer, José Octávio Costa Filho, M.D. Oct 28, 2019Rafael Pharmaceuticals Reaches Milestone of 25 Active Sites for Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (devimistat) in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) Oct 24, 2019Rafael Pharmaceuticals Announces Expansion into South Korea of Pivotal Phase 3 Trial of CPI-613® (devimistat) in Patients with Metastatic Pancreatic Cancer Aug 05, 2019News from LipoMedix: LipoMedix Appoints New Members to Board of Directors and Creates New Executive Committee Apr 13, 2018Press Release from Rafael Pharmaceuticals: Clinical Cancer Research Publishes Phase I Data from a Study of Rafael Pharmaceuticals' Lead CPI-613 Compound in Combination with High-Dose Cytarabine and Mitoxantrone for Relapsed or Refractory Acute Myeloid Leukemia 1 2 3 4 5 << < > >>